Details of the Drug

General Information of Drug (ID: DM7ISKJ)

Drug Name

Nisoldipine

Synonyms

Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

388.4

Topological Polar Surface Area (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 - 12 hours [4]
Metabolism: The drug is metabolized via the cytochrome P450 3A4 [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.25048 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.003% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 5.5 L/kg [4]

Chemical Identifiers

Formula: C20H24N2O6
IUPAC Name: 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI: InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
InChIKey: VKQFCGNPDRICFG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4499
ChEBI ID: CHEBI:76917
CAS Number: 63675-72-9
DrugBank ID: DB00401
TTD ID: D0S5CU
VARIDT ID: DR00668
INTEDE ID: DR1165
ACDINA ID: D00472

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Blocker	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)_{Main DME}	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)_{Main DME}	DERD86B	CP3A7_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nisoldipine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acebutolol	DM0TI4U	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Acebutolol.	Hypertension [BA00-BA04]	[46]
Bisoprolol	DM3UZ95	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Bisoprolol.	Hypertension [BA00-BA04]	[46]
Penbutolol	DM4ES8F	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Penbutolol.	Hypertension [BA00-BA04]	[46]
Nebivolol	DM7F1PA	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Nebivolol.	Hypertension [BA00-BA04]	[46]
Labetalol	DMK8U72	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Labetalol.	Hypertension [BA00-BA04]	[46]
-----------

Coadministration of a Drug Treating the Disease Different from Nisoldipine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Nisoldipine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[47]
Arn-509	DMT81LZ	Major	Increased metabolism of Nisoldipine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[48]
Magnesium Sulfate	DMVEK07	Moderate	Additive neuromuscular blocking effects by the combination of Nisoldipine and Magnesium Sulfate.	Acute pain [MG31]	[49]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Nisoldipine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[50]
Mitotane	DMU1GX0	Major	Increased metabolism of Nisoldipine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[48]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Nisoldipine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[50]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Nisoldipine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[51]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Promazine.	Appearance/behaviour symptom [MB23]	[52]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Nisoldipine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[53]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Nisoldipine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[53]
Zileuton	DMVRIC2	Minor	Decreased metabolism of Nisoldipine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[54]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Linezolid.	Bacterial infection [1A00-1C4Z]	[55]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Nisoldipine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[56]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Cariprazine.	Bipolar disorder [6A60]	[52]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Nisoldipine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[57]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Nisoldipine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Nisoldipine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[59]
Sotalol	DML60TN	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Sotalol.	Cardiac arrhythmia [BC9Z]	[46]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Nisoldipine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[51]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Nisoldipine caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[51]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Nisoldipine caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[51]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Nisoldipine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[60]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Nisoldipine and Pasireotide.	Cushing syndrome [5A70]	[61]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Nisoldipine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[62]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Nisoldipine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[61]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Nisoldipine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Selegiline.	Depression [6A70-6A7Z]	[55]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Isocarboxazid.	Depression [6A70-6A7Z]	[55]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Tranylcypromine.	Depression [6A70-6A7Z]	[55]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Nisoldipine and OPC-34712.	Depression [6A70-6A7Z]	[52]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Phenelzine.	Depression [6A70-6A7Z]	[55]
Primidone	DM0WX6I	Major	Increased metabolism of Nisoldipine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Nisoldipine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[64]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Nisoldipine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Nisoldipine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[66]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Nisoldipine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Nisoldipine caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[67]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Nisoldipine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Nisoldipine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[68]
Nadolol	DMW6GVL	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Nadolol.	Essential hypertension [BA00]	[46]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Nisoldipine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[69]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Nisoldipine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[70]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Nisoldipine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[71]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Nisoldipine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[70]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Nisoldipine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[72]
Carteolol	DMFMDOB	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Carteolol.	Glaucoma [9C61]	[46]
Metipranolol	DMJMVKI	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Metipranolol.	Glaucoma [9C61]	[73]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Levobetaxolol.	Glaucoma [9C61]	[73]
Levobunolol	DMTNFCQ	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Levobunolol.	Glaucoma [9C61]	[73]
Carvedilol	DMHTEAO	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Carvedilol.	Heart failure [BD10-BD1Z]	[46]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Nisoldipine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[74]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Nisoldipine caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[75]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Nisoldipine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[74]
Rifapentine	DMCHV4I	Major	Increased metabolism of Nisoldipine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[48]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Procarbazine.	Hodgkin lymphoma [2B30]	[55]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Nisoldipine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[76]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Nisoldipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[77]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Nisoldipine due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[78]
Tipranavir	DM8HJX6	Moderate	Accelerated clearance of Nisoldipine due to the transporter induction by Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[79]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Nisoldipine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[80]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Nisoldipine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[81]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Nisoldipine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[82]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Nisoldipine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[77]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Nisoldipine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[83]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Nisoldipine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[84]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Nisoldipine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[85]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Nisoldipine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[51]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Propiomazine.	Insomnia [7A00-7A0Z]	[52]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Nisoldipine and ITI-007.	Insomnia [7A00-7A0Z]	[52]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Nisoldipine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[86]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Nisoldipine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[50]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Nisoldipine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[87]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Nisoldipine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[88]
LGX818	DMNQXV8	Moderate	Increased metabolism of Nisoldipine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[89]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Nisoldipine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[50]
Propranolol	DM79NTF	Moderate	Increased risk of cardiac depression by the combination of Nisoldipine and Propranolol.	Migraine [8A80]	[46]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Nisoldipine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[90]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Nisoldipine and Thalidomide.	Multiple myeloma [2A83]	[70]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Nisoldipine and Siponimod.	Multiple sclerosis [8A40]	[70]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Nisoldipine and Fingolimod.	Multiple sclerosis [8A40]	[91]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Nisoldipine and Ozanimod.	Multiple sclerosis [8A40]	[92]
Rifabutin	DM1YBHK	Major	Increased metabolism of Nisoldipine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[48]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Nisoldipine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[93]
Modafinil	DMYILBE	Moderate	Increased metabolism of Nisoldipine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[70]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Prochlorperazine.	Nausea/vomiting [MD90]	[52]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Promethazine.	Nausea/vomiting [MD90]	[52]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Nisoldipine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[94]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Nisoldipine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[95]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Safinamide.	Parkinsonism [8A00]	[55]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Rasagiline.	Parkinsonism [8A00]	[55]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Nisoldipine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[96]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Nisoldipine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[97]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Nisoldipine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[98]
Enzalutamide	DMGL19D	Major	Increased metabolism of Nisoldipine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[48]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Nisoldipine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[50]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Nisoldipine due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[50]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[52]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[52]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[52]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Nisoldipine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[99]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Nisoldipine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[100]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Nisoldipine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[50]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Nisoldipine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[50]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Nisoldipine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[50]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Nisoldipine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[50]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Nisoldipine due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[50]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Quetiapine.	Schizophrenia [6A20]	[52]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Mesoridazine.	Schizophrenia [6A20]	[52]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Thioridazine.	Schizophrenia [6A20]	[52]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Aripiprazole.	Schizophrenia [6A20]	[52]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Iloperidone.	Schizophrenia [6A20]	[52]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Paliperidone.	Schizophrenia [6A20]	[52]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Loxapine.	Schizophrenia [6A20]	[52]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Haloperidol.	Schizophrenia [6A20]	[52]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Perphenazine.	Schizophrenia [6A20]	[52]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Molindone.	Schizophrenia [6A20]	[52]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Chlorpromazine.	Schizophrenia [6A20]	[52]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Thiothixene.	Schizophrenia [6A20]	[52]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Trifluoperazine.	Schizophrenia [6A20]	[52]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Risperidone.	Schizophrenia [6A20]	[52]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Amisulpride.	Schizophrenia [6A20]	[52]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Asenapine.	Schizophrenia [6A20]	[52]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Nisoldipine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[101]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Nisoldipine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[50]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Nisoldipine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[70]
Armodafinil	DMGB035	Moderate	Increased metabolism of Nisoldipine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[70]
LEE011	DMMX75K	Moderate	Decreased metabolism of Nisoldipine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[102]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Nisoldipine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[50]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Nisoldipine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[103]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Nisoldipine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[100]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Nisoldipine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[100]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[52]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Nisoldipine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[104]
-----------


⏷ Show the Full List of 133 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nisoldipine 17 mg tablet	17 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 8.5 mg tablet	8.5 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 40 mg tablet	40 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 20 mg tablet	20 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 34 mg tablet	34 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 25.5 mg tablet	25.5 mg	24 HR Extended Release Oral Tablet	Oral
Nisoldipine 25.5 mg tablet	25.5 mg	24 HR Extended Release Tablet	Oral
Nisoldipine 30 mg tablet	30 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2524).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 079051.
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
8	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10	Drug Interactions Flockhart Table
11	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
24	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
25	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
26	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
27	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
28	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
29	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
30	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
31	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
32	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
33	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
34	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
35	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
36	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
37	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
38	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
39	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
40	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
41	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
42	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
43	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
44	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
45	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
46	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
47	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
48	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
49	Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
50	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51	Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
52	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
53	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
54	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
55	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
56	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
57	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
58	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
59	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
60	He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
61	Canadian Pharmacists Association.
62	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
63	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
64	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
65	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
66	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
67	Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
68	Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
69	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
70	Cerner Multum, Inc. "Australian Product Information.".
71	Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
72	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
73	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
74	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
75	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
76	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
77	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
78	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
79	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
80	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
81	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
82	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
83	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
84	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
85	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
86	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
87	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
88	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
89	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
90	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
91	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
92	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
93	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
94	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
95	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
96	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
97	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
98	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
99	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
100	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
101	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
102	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
103	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
104	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.